Can Wildfire Smoke Stop Asthma Biologics from Working?
At a Glance
No, wildfire smoke does not cause asthma biologics to permanently stop working. Smoke triggers a different type of lung inflammation than the biologic targets, causing a temporary breakthrough exacerbation. Your medication is still actively managing your underlying eosinophilic asthma.
No, a severe asthma flare-up triggered by wildfire smoke will not cause your biologic medication to permanently stop working. While experiencing an attack while on a biologic can be frightening, this is considered a breakthrough exacerbation. [1] Your medication is still actively working in your body, but the intense environmental trigger has temporarily overwhelmed your lungs through different inflammatory pathways. [2][3]
How Wildfire Smoke Bypasses Your Biologic
Biologic medications for Severe Refractory Eosinophilic Asthma (SREA)—such as mepolizumab, benralizumab, and dupilumab—work by targeting specific parts of your immune system, primarily blocking Type 2 (T2) inflammation driven by eosinophils (a specific type of white blood cell). [4][1]
Wildfire smoke contains high levels of fine particulate matter (PM2.5), which is inhaled deeply into the lungs. [5][6] Wildfire-derived PM2.5 is particularly hazardous and can trigger asthma attacks through direct irritation and oxidative stress. [7][8] Instead of only triggering eosinophils, severe pollution and smoke often activate a completely different immune response, known as neutrophilic inflammation (driven by neutrophils, another type of white blood cell). [9][10]
Because your biologic is designed to act like a highly specialized shield against eosinophils, it does not block the neutrophilic inflammation or direct toxicity caused by inhaling smoke. [11][12] The smoke essentially bypasses the biologic’s defenses, causing symptoms to flare up even while the drug continues to suppress your underlying eosinophilic asthma.
Breakthrough Exacerbations vs. Medication Failure
When your symptoms spike during a heavy smoke event, it is a breakthrough exacerbation—meaning the environmental trigger was strong enough to break through your asthma control temporarily. [1] There is no evidence that environmental triggers like wildfire smoke cause a biologic to permanently lose efficacy. [2][5]
True medication failure—where a biologic permanently stops working—usually happens when the body’s immune system develops anti-drug antibodies (ADAs). [13][4] These antibodies can neutralize the medication over time. While the idea of your immune system rejecting the drug can be anxiety-inducing, it is a separate, internal immune process that is evaluated by doctors on a case-by-case basis and is completely unrelated to breathing in smoke or having an asthma attack. [14]
Treating the Flare-Up
Because your biologic cannot block the effects of wildfire smoke, your doctor will likely treat this flare-up similarly to how they would if you weren’t on a biologic. This often involves increased use of rescue inhalers or a short course of oral corticosteroids (OCS) to calm the immediate irritation and alternative inflammatory pathways. [15][16]
While needing OCS can be incredibly discouraging when you are on a biologic—and feel like a massive setback—a short burst is sometimes necessary to quiet this different type of inflammation. Do not stop taking your biologic during a flare-up unless instructed by your doctor; it is still working in the background to manage your baseline eosinophilic asthma.
Safety Note: Always follow your Asthma Action Plan. If your rescue medications are not providing relief during a smoke flare-up, seek emergency medical care immediately.
Protecting Yourself During Wildfire Season
Since your biologic cannot shield you from PM2.5, proactive prevention is critical when smoke rolls in:
- Monitor the AQI: Track local air quality indices and stay indoors when levels are unhealthy.
- Use HEPA Filters: Run high-efficiency particulate air (HEPA) purifiers indoors to capture PM2.5.
- Wear an N95 Mask: If you must go outside during a smoke event, a well-fitted N95 mask can significantly reduce the amount of particulate matter you inhale.
Common questions in this guide
Can wildfire smoke cause my asthma biologic to permanently fail?
Why do I still get asthma flare-ups from smoke while on a biologic?
How do I know if my asthma biologic has actually stopped working?
What should I do if I have a smoke-triggered asthma attack while on a biologic?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my specific action plan during heavy smoke days, knowing my biologic won't block PM2.5?
- 2.Should I temporarily increase my inhaled controller medications before the smoke gets bad?
- 3.Since my biologic targets eosinophils, how will we know if this smoke-related flare-up is being driven by neutrophilic inflammation instead?
- 4.At what point during a breakthrough exacerbation should I contact the office for oral steroids rather than relying on my rescue inhaler?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (16)
- 1
IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma.
Luo J, Chen W, Liu W, et al.
Mucosal immunology 2024; (17(4)):524-536 doi:10.1016/j.mucimm.2024.03.005.
PMID: 38493955 - 2
Diagnosis and Management of T2-High Asthma.
Coverstone AM, Seibold MA, Peters MC
The journal of allergy and clinical immunology. In practice 2020; (8(2)):442-450 doi:10.1016/j.jaip.2019.11.020.
PMID: 32037108 - 3
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M, Corren J, Pavord ID, et al.
The New England journal of medicine 2018; (378(26)):2486-2496 doi:10.1056/NEJMoa1804092.
PMID: 29782217 - 4
Immunogenicity of biologics used in the treatment of asthma.
Neunie OAM, Rabbani W, Baker D, et al.
Human antibodies 2024; (32(3)):121-128 doi:10.3233/HAB-240002.
PMID: 38905039 - 5
Short-Term Exposure Effect of Ambient Fine Particulate Matter, Ozone and Cold Temperature on Emergency Room Visits for Asthma Patients.
Cheng CG, Yen SY, Hsiao CC, et al.
Toxics 2023; (11(2)) doi:10.3390/toxics11020094.
PMID: 36850970 - 6
Effects of short-term exposure to particulate matter on emergency department admission and hospitalization for asthma exacerbations in Brescia district.
Pini L, Giordani J, Concoreggi C, et al.
The Journal of asthma : official journal of the Association for the Care of Asthma 2022; (59(7)):1290-1297 doi:10.1080/02770903.2021.1929310.
PMID: 33980121 - 7
Particulate matter and emergency visits for asthma: a time-series study of their association in the presence and absence of wildfire smoke in Reno, Nevada, 2013-2018.
Kiser D, Metcalf WJ, Elhanan G, et al.
Environmental health : a global access science source 2020; (19(1)):92 doi:10.1186/s12940-020-00646-2.
PMID: 32854703 - 8
Examining fine particulate matter and cause-specific morbidity during the 2017 North San Francisco Bay wildfires.
Malig BJ, Fairley D, Pearson D, et al.
The Science of the total environment 2021; (787()):147507 doi:10.1016/j.scitotenv.2021.147507.
PMID: 35142610 - 9
Relationship between Th17-mediated immunity and airway inflammation in childhood neutrophilic asthma.
Wei Q, Liao J, Jiang M, et al.
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2021; (17(1)):4 doi:10.1186/s13223-020-00504-3.
PMID: 33407843 - 10
Biomarkers in the Management of Difficult Asthma.
Schleich F, Demarche S, Louis R
Current topics in medicinal chemistry 2016; (16(14)):1561-73 doi:10.2174/1568026616666151015093406.
PMID: 26467509 - 11
Evaluating Severe Therapy-Resistant Asthma in Children: Diagnostic and Therapeutic Strategies.
Bush A
Medicina (Kaunas, Lithuania) 2024; (60(11)) doi:10.3390/medicina60111799.
PMID: 39596984 - 12
Asthma Biologics Across the T2 Spectrum of Inflammation in Severe Asthma: Biomarkers and Mechanism of Action.
Lindsley AW, Lugogo N, Reeh KAG, et al.
Journal of asthma and allergy 2025; (18()):33-57 doi:10.2147/JAA.S496630.
PMID: 39830595 - 13
Comparable immunogenicity of new modality biotherapeutics delivered subcutaneously or intravenously in non-human primates.
Koch V, Lechmann M, Bray-French K, et al.
Journal of immunotoxicology 2025; (22(1)):2537408 doi:10.1080/1547691X.2025.2537408.
PMID: 40785401 - 14
Evaluating the Immunogenicity Risk of Protein Therapeutics by Augmenting T Cell Epitope Prediction with Clinical Factors.
Hu Z, Wu P, Swanson SJ
The AAPS journal 2025; (27(1)):33 doi:10.1208/s12248-024-01003-8.
PMID: 39849284 - 15
A Practical Approach to Severe Asthma in Children.
Barsky EE, Giancola LM, Baxi SN, Gaffin JM
Annals of the American Thoracic Society 2018; (15(4)):399-408 doi:10.1513/AnnalsATS.201708-637FR.
PMID: 29220200 - 16
Multimorbidity in Difficult Asthma: The Need for Personalised and Non-Pharmacological Approaches to Address a Difficult Breathing Syndrome.
Varkonyi-Sepp J, Freeman A, Ainsworth B, et al.
Journal of personalized medicine 2022; (12(9)) doi:10.3390/jpm12091435.
PMID: 36143220
This page explains how environmental triggers like wildfire smoke interact with asthma biologics for educational purposes only. Always consult your pulmonologist or allergist and follow your personal Asthma Action Plan during a flare-up.
Get notified when new evidence is published on Severe Refractory Eosinophilic Asthma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.